428 related articles for article (PubMed ID: 17567647)
1. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Geisler T; Kapp M; Göhring-Frischholz K; Daub K; Dösch C; Bigalke B; Langer H; Herdeg C; Gawaz M
Heart; 2008 Jun; 94(6):743-7. PubMed ID: 17567647
[TBL] [Abstract][Full Text] [Related]
2. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study.
Collet JP; Silvain J; Landivier A; Tanguy ML; Cayla G; Bellemain A; Vignolles N; Gallier S; Beygui F; Pena A; Montalescot G
Circulation; 2008 Sep; 118(12):1225-33. PubMed ID: 18765393
[TBL] [Abstract][Full Text] [Related]
3. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
4. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
[TBL] [Abstract][Full Text] [Related]
5. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Guthikonda S; Alviar CL; Vaduganathan M; Arikan M; Tellez A; DeLao T; Granada JF; Dong JF; Kleiman NS; Lev EI
J Am Coll Cardiol; 2008 Aug; 52(9):743-9. PubMed ID: 18718422
[TBL] [Abstract][Full Text] [Related]
6. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
7. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
8. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.
Geisler T; Langer H; Wydymus M; Göhring K; Zürn C; Bigalke B; Stellos K; May AE; Gawaz M
Eur Heart J; 2006 Oct; 27(20):2420-5. PubMed ID: 17005534
[TBL] [Abstract][Full Text] [Related]
9. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
10. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Eshtehardi P; Windecker S; Cook S; Billinger M; Togni M; Garachemani A; Meier B; Hess OM; Wenaweser P
Am Heart J; 2010 May; 159(5):891-898.e1. PubMed ID: 20435201
[TBL] [Abstract][Full Text] [Related]
11. Platelet collagen receptor glycoprotein VI as a possible novel indicator for the acute coronary syndrome.
Bigalke B; Geisler T; Stellos K; Langer H; Daub K; Kremmer E; Seizer P; May AE; Lindemann S; Gawaz M
Am Heart J; 2008 Jul; 156(1):193-200. PubMed ID: 18585516
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
[TBL] [Abstract][Full Text] [Related]
13. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
Guha S; Sardar P; Guha P; Roy S; Mookerjee S; Chakrabarti P; Deb PK; Chaudhuri U; Deb S; Karmakar R; Dasgupta AK; Lahiri P
Indian Heart J; 2009; 61(1):68-73. PubMed ID: 19729693
[TBL] [Abstract][Full Text] [Related]
14. Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.
Zuern CS; Geisler T; Lutilsky N; Winter S; Schwab M; Gawaz M
Thromb Res; 2010 Feb; 125(2):e51-4. PubMed ID: 19781742
[TBL] [Abstract][Full Text] [Related]
15. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
16. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
[TBL] [Abstract][Full Text] [Related]
17. Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease.
Li J; Jian Z; Huang L; Guo H; Huang J; Qian D; Fu W; Li A; Song Y
Biomed Pharmacother; 2009 Sep; 63(8):608-12. PubMed ID: 19019624
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
19. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
20. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
